​

Allakos (ALLK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALLK Stock Forecast

Allakos stock forecast is as follows: an average price target of $1.00 (represents a -22.48% downside from ALLK’s last price of $1.29) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ALLK Price Target

The average price target for Allakos (ALLK) is $1.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential -22.48% downside from ALLK's last price of $1.29.

ALLK Analyst Ratings

Buy

According to 4 Wall Street analysts, Allakos's rating consensus is 'Buy'. The analyst rating breakdown for ALLK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Allakos Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 18, 2024Farzin HaqueJefferies$1.00$0.8221.43%-22.48%
Jan 17, 2024Kevin StrangJefferies$3.00$1.19152.10%132.56%
Oct 15, 2021Brian ChengCantor Fitzgerald$218.00$107.48102.83%16799.22%

The latest Allakos stock forecast, released on Jul 18, 2024 by Farzin Haque from Jefferies, set a price target of $1.00, which represents a 21.43% increase from the stock price at the time of the forecast ($0.82), and a -22.48% decrease from ALLK last price ($1.29).

Allakos Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$2.00
Last Closing Price$1.29$1.29$1.29
Upside/Downside-100.00%-100.00%55.04%

In the current month, the average price target of Allakos stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Allakos's last price of $1.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2024Cowen & Co.HoldHoldHold
Oct 11, 2024Piper SandlerOverweightOverweightHold
Jun 26, 2024Cowen & Co.HoldHoldHold
Jun 26, 2024Piper SandlerOverweightOverweightHold
Dec 18, 2023William BlairOutperformUpgrade
May 11, 2023JefferiesBuyUpgrade

Allakos's last stock rating was published by Cowen & Co. on Oct 11, 2024. The company gave ALLK a "Hold" rating, the same as its previous rate.

Allakos Financial Forecast

Allakos Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Allakos's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ALLK's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Allakos EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict ALLK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Allakos's previous annual EBITDA (undefined) of $NaN.

Allakos Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-17.80M$-12.69M$-12.24M$-12.69M$-16.77M$-22.09M$-29.48M
High Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-17.80M$-12.69M$-12.24M$-12.69M$-12.57M$-22.09M$-29.48M
Low Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-17.80M$-12.69M$-12.24M$-12.69M$-19.91M$-22.09M$-29.48M
Surprise %-----------

Allakos's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALLK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Allakos SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Allakos's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ALLK last annual SG&A of $NaN (undefined).

Allakos EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.21$-0.21$-0.22$-0.21$-0.20$-0.14$-0.14$-0.14$-0.19$-0.25$-0.33
High Forecast$-0.21$-0.21$-0.22$-0.21$-0.20$-0.14$-0.14$-0.14$-0.14$-0.25$-0.33
Low Forecast$-0.21$-0.21$-0.22$-0.21$-0.20$-0.14$-0.14$-0.14$-0.22$-0.25$-0.33
Surprise %-----------

According to undefined Wall Street analysts, Allakos's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALLK previous annual EPS of $NaN (undefined).

Allakos Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ALLOAllogene Therapeutics$2.07$29.001300.97%Buy
SPROSpero Therapeutics$1.04$10.00861.54%Buy
SGMOSangamo Therapeutics$2.82$12.00325.53%Buy
HRTXHeron Therapeutics$1.65$7.00324.24%Buy
SANASana Bio$1.91$8.00318.85%Buy
NXTCNextCure$0.90$3.00233.33%Buy
CTMXCytomX Therapeutics$1.13$3.47207.08%Buy
ARVNArvinas$19.10$58.50206.28%Buy
ANNXAnnexon$4.88$14.00186.89%Buy
FATEFate Therapeutics$1.88$5.00165.96%Buy
ASMBAssembly Biosciences$14.28$35.50148.60%Buy
KURAKura Oncology$9.74$23.33139.53%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
RCUSArcus Biosciences$16.08$31.7197.20%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
CRBUCaribou Biosciences$1.94$3.0054.64%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
ATRAAtara Biotherapeutics$10.35$14.0035.27%Sell
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
CRNXCrinetics Pharmaceuticals$55.37$69.0024.62%Buy
ALLKAllakos$1.08$1.00-7.41%Buy

ALLK Forecast FAQ

Is Allakos a good buy?

Yes, according to 4 Wall Street analysts, Allakos (ALLK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of ALLK's total ratings.

What is ALLK's price target?

Allakos (ALLK) average price target is $1 with a range of $1 to $1, implying a -22.48% from its last price of $1.29. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Allakos stock go up soon?

According to Wall Street analysts' prediction for ALLK stock, the company can go down by -22.48% (from the last price of $1.29 to the average price target of $1), down by -22.48% based on the highest stock price target, and down by -22.48% based on the lowest stock price target.

Can Allakos stock reach $2?

ALLK's average twelve months analyst stock price target of $1 does not support the claim that Allakos can reach $2 in the near future.

What are Allakos's analysts' financial forecasts?

Allakos's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-55.417M (high $-55.417M, low $-55.417M), average SG&A $0 (high $0, low $0), and average EPS is $-0.623 (high $-0.623, low $-0.623). ALLK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.67M (high $-75.67M, low $-75.67M), average SG&A $0 (high $0, low $0), and average EPS is $-0.85 (high $-0.85, low $-0.85).